ATXS May 2024 22.500 call
| Previous Close | 0.1500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 22.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.0500 - 0.1500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 62 |
Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 02, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria’s common stock on May 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
Business WireAstria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
BOSTON, April 09, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
GuruFocus.comChief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc (NASDAQ:ATXS), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat debilitating diseases, has reported an insider sale according to a recent SEC filing.
